<rdf:RDF xmlns:crm='http://www.cidoc-crm.org/rdfs/cidoc_crm_v5.0.2_english_label.rdfs#' xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:dcterms='http://purl.org/dc/terms/' xmlns:doap='http://usefulinc.com/ns/doap#' xmlns:edm='http://www.europeana.eu/schemas/edm/' xmlns:ekt='https://www.semantics.gr/authorities/schemanamespaces/ekt#' xmlns:foaf='http://xmlns.com/foaf/0.1/' xmlns:ore='http://www.openarchives.org/ore/terms/' xmlns:owl='http://www.w3.org/2002/07/owl#' xmlns:rdaGr2='http://rdvocab.info/ElementsGr2/' xmlns:rdf='http://www.w3.org/1999/02/22-rdf-syntax-ns#' xmlns:rdfs='http://www.w3.org/2000/01/rdf-schema#' xmlns:skos='http://www.w3.org/2004/02/skos/core#' xmlns:svcs='http://rdfs.org/sioc/services#' xmlns:wgs84_pos='http://www.w3.org/2003/01/geo/wgs84_pos#' xmlns:xalan='http://xml.apache.org/xalan'><edm:ProvidedCHO rdf:about='https://www.openarchives.gr/aggregator-openarchives/edm/gastro/000025-542'><dc:creator>Hatzakis, A.</dc:creator><dc:creator>Tassopoulos, N. C.</dc:creator><dc:creator>Vafiadou, Irini</dc:creator><dc:creator>Papatheodoridis, G. V.</dc:creator><dc:creator>Delladetsima, Ioanna</dc:creator><dc:description xml:lang='en'>The best interferon-alfa (IFNÎ±) regimen for HBeAg negative
chronic hepatitis B has not been established yet. We evaluated
the efficacy of three regimens of IFNÎ± in 75 patients with
histologically documented HBeAg negative chronic hepatitis
B, who were randomly allocated to receive IFNÎ±-2b thrice
weekly in a dose of: 3MU for 12 months (Group A, n=25);
5 MU for 6 months and 3 MU for another 6 months (Group
B, n=25); and 3 MU for 6 months and 1 MU for another 6
months (Group C, n=25). Initial biochemical response was
observed in 71% of the 75 patients and initial virological response (undetectable serum HBV DNA by bDNA assay) in
38% of the patients with pre-treatment detectable serum HBV
DNA. The decline of HBV DNA levels at the end of therapy
was significant in group A (P=0.02) or B (P=0.004), but not
in group C. Sustained biochemical and virological response
rates (at 6 months after the end of therapy) were 35% and
22% respectively, without any significant difference among
the three groups. There was a significant improvement in the
grading (P</dc:description><dc:format>application/pdf</dc:format><dc:identifier>http://www.annalsgastro.gr/index.php/annalsgastro/article/view/542</dc:identifier><dc:language>eng</dc:language><dc:publisher xml:lang='en'>Hellenic Society of Gastroenterology</dc:publisher><dc:relation rdf:resource='http://www.annalsgastro.gr/index.php/annalsgastro/article/view/542/425'></dc:relation><dc:source>1792-7463</dc:source><dc:source>1108-7471</dc:source><dc:source xml:lang='en'>Annals of Gastroenterology; Volume 19, No 4 (2006)</dc:source><dc:subject rdf:resource='http://semantics.gr/authorities/EKT-voc-classifier/657834409'></dc:subject><dc:title xml:lang='en'>Efficacy of different doses of 12-month Interferon alfa therapy in patients with HBeAg negative chronic hepatitis B: A randomized trial</dc:title><dc:type rdf:resource='http://semantics.gr/authorities/openarchives-item-types/Journal-part'></dc:type><dc:type>info:eu-repo/semantics/article</dc:type><dc:type>info:eu-repo/semantics/publishedVersion</dc:type><dc:type rdf:resource='http://semantics.gr/authorities/openarchives-item-types/Scientific-article'></dc:type><dcterms:created>2007-04-12</dcterms:created></edm:ProvidedCHO><skos:Concept rdf:about='http://semantics.gr/authorities/openarchives-item-types/Journal-part'><skos:prefLabel xml:lang='el'>Δημοσίευση σε περιοδικό</skos:prefLabel><skos:prefLabel xml:lang='en'>Publication in journal</skos:prefLabel><skos:broader rdf:resource='http://semantics.gr/authorities/openarchives-item-types/Issue-segment'></skos:broader></skos:Concept><skos:Concept rdf:about='http://semantics.gr/authorities/EKT-voc-classifier/657834409'><skos:prefLabel xml:lang='el'>Γαστροεντερολογία</skos:prefLabel><skos:prefLabel xml:lang='en'>Gastroenterology</skos:prefLabel><skos:broader rdf:resource='http://semantics.gr/authorities/EKT-voc-classifier/1368266523'></skos:broader><skos:exactMatch rdf:resource='http://semantics.gr/authorities/EKT-voc/657834409'></skos:exactMatch><skos:exactMatch rdf:resource='http://id.loc.gov/authorities/subjects/sh85053479'></skos:exactMatch><skos:note xml:lang='en'>isi -Gastroenterology &amp; Hepatology covers resources on the anatomy, physiology, biochemistry, and pathology of the digestive system. This category includes specific resources on the prognosis and treatment of digestive diseases; stomach ulcers; metabolic, genetic, infectious and chemically induced diseases of the liver; colitis; diseases of the pancreas and diseases of the rectum.</skos:note></skos:Concept><skos:Concept rdf:about='http://semantics.gr/authorities/openarchives-item-types/Scientific-article'><skos:prefLabel xml:lang='el'>Επιστημονικό άρθρο</skos:prefLabel><skos:prefLabel xml:lang='en'>Scientific article</skos:prefLabel><skos:broader rdf:resource='http://semantics.gr/authorities/openarchives-item-types/arthro'></skos:broader></skos:Concept><ore:Aggregation rdf:about='https://www.openarchives.gr/aggregator-openarchives/edm/aggregation/provider/000025-542%231'><edm:aggregatedCHO rdf:resource='https://www.openarchives.gr/aggregator-openarchives/edm/gastro/000025-542'></edm:aggregatedCHO><edm:dataProvider>Ελληνική Γαστροεντερολογική Εταιρία</edm:dataProvider><edm:isShownAt rdf:resource='http://www.annalsgastro.gr/index.php/annalsgastro/article/view/542'></edm:isShownAt><edm:provider>Greek Aggregator OpenArchives.gr | National Documentation Centre (EKT)</edm:provider><edm:rights>other</edm:rights></ore:Aggregation></rdf:RDF>